Volume | 3,769 |
|
|||||
News | - | ||||||
Day High | 12.00 | Low High |
|||||
Day Low | 11.72 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Oculis Holding AG | OCS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.00 | 11.72 | 12.00 | 11.80 | 11.80 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
56 | 3,769 | US$ 11.81 | US$ 44,515 | - | 9.05 - 14.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 47 | US$ 11.88 | USD |
Oculis Holding AG Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 432.47M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Oculis News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.00 | 12.05 | 11.6982 | 11.94 | 10,613 | -0.20 | -1.67% |
1 Month | 11.91 | 12.0796 | 11.58 | 11.88 | 8,974 | -0.11 | -0.92% |
3 Months | 11.80 | 13.30 | 10.55 | 11.96 | 39,133 | 0.00 | 0.00% |
6 Months | 11.24 | 14.465 | 9.60 | 12.06 | 36,980 | 0.56 | 4.98% |
1 Year | 11.75 | 14.50 | 9.05 | 11.92 | 28,054 | 0.05 | 0.43% |
3 Years | 10.95 | 14.50 | 6.26 | 11.48 | 27,687 | 0.85 | 7.76% |
5 Years | 10.95 | 14.50 | 6.26 | 11.48 | 27,687 | 0.85 | 7.76% |
Oculis Description
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. |